Bruker (NASDAQ:BRKR) had its price objective raised by Jefferies Financial Group from $45.00 to $56.00 in a report released on Friday, The Fly reports. Jefferies Financial Group currently has a buy rating on the medical research company’s stock. Jefferies Financial Group also issued estimates for Bruker’s Q1 2020 earnings at $0.41 EPS, Q3 2020 earnings at $0.45 EPS, Q4 2020 earnings at $0.56 EPS and FY2020 earnings at $1.84 EPS.
Other equities research analysts have also issued reports about the stock. BTIG Research lifted their price target on shares of Bruker to $57.00 and gave the company a buy rating in a research note on Friday. BidaskClub upgraded shares of Bruker from a hold rating to a buy rating in a research note on Wednesday, June 5th. Deutsche Bank upgraded shares of Bruker from a hold rating to a buy rating and lifted their price target for the company from $40.00 to $50.00 in a research note on Friday, April 12th. Zacks Investment Research lowered shares of Bruker from a buy rating to a hold rating in a research note on Tuesday, April 16th. Finally, UBS Group upgraded shares of Bruker from a sell rating to a neutral rating and set a $43.00 price target on the stock in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $48.20.
Shares of NASDAQ:BRKR opened at $48.60 on Friday. Bruker has a 12 month low of $26.10 and a 12 month high of $49.88. The company has a current ratio of 2.12, a quick ratio of 1.27 and a debt-to-equity ratio of 0.42. The stock’s fifty day moving average is $43.69. The firm has a market capitalization of $7.65 billion, a price-to-earnings ratio of 34.71, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The firm had revenue of $461.40 million for the quarter, compared to analyst estimates of $450.46 million. During the same period in the previous year, the business earned $0.24 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. Equities analysts predict that Bruker will post 1.62 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 21st. Stockholders of record on Monday, June 3rd were paid a dividend of $0.04 per share. The ex-dividend date was Friday, May 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.33%. Bruker’s dividend payout ratio is presently 11.43%.
In other news, Director Marc A. Kastner sold 1,374 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the transaction, the director now directly owns 10,811 shares in the company, valued at approximately $451,791.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Frank H. Laukien sold 400,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the transaction, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The disclosure for this sale can be found here. Insiders have sold a total of 801,374 shares of company stock worth $33,241,419 over the last 90 days. 26.50% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in BRKR. O Shaughnessy Asset Management LLC bought a new stake in shares of Bruker during the 1st quarter worth about $35,000. Captrust Financial Advisors boosted its holdings in shares of Bruker by 164.7% during the 4th quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock worth $54,000 after buying an additional 1,135 shares during the period. ARP Americas LP bought a new stake in shares of Bruker during the 1st quarter worth about $212,000. CIBC Asset Management Inc bought a new stake in shares of Bruker during the 1st quarter worth about $214,000. Finally, SG Americas Securities LLC bought a new stake in shares of Bruker during the 4th quarter worth about $176,000. Institutional investors own 66.73% of the company’s stock.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: What is the market perform rating?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.